Updated July 2026 · 8 min read

Desmopressin (DDAVP): The ICU Nurse's Guide

Part of the ICU Emergencies Hub — browse every related guide in one place.

Desmopressin is one of those drugs that shows up in three completely unrelated situations, which is exactly what makes it confusing. The same little vial can be treating runaway urine output, a bleeding uremic patient, or a bleed in von Willebrand disease. Understanding that one molecule does three jobs — and the sodium trap that ties two of them together — is core ICU pharmacology that carries straight into anesthesia practice.

Why one drug does three jobs

Native ADH (vasopressin) hits two receptor types: V1 (vascular — squeezes vessels) and V2 (kidney — retains water; and, importantly, triggers release of von Willebrand factor from the vessel wall). Desmopressin is engineered to be selective for V2 and to last longer. Stripping out the V1 effect is what makes it useful: you get the water-conserving and clotting-factor-releasing actions without the potent vasoconstriction of vasopressin. So the "antidiuretic" job and the "hemostatic" job are two faces of the same V2 receptor.

Job 1: Central diabetes insipidus

In central DI the pituitary isn't making ADH, so the kidney can't concentrate urine — the patient pours out large volumes of dilute urine and the serum sodium climbs. This is common after neurosurgery, pituitary injury, and in brain death. Desmopressin replaces the missing hormone: urine output drops and concentrates, and the sodium stabilizes.

The bedside skill is tracking the response. Watch hourly urine output, urine specific gravity/osmolality, and serial sodiums. A classic clue that a dose is wearing off is urine output climbing again with falling urine concentration. Don't confuse the polyuria of DI (dilute) with the polyuria of hyperglycemia or a fluid-mobilization diuresis — the urine studies and glucose sort them out.

Job 2: Bleeding from uremia or antiplatelet effect

Uremic patients bleed because the toxins impair platelet function even when the platelet count is normal. Desmopressin transiently improves that platelet function by releasing von Willebrand factor, which helps platelets stick. It's used to help control or prevent bleeding — before a procedure in a uremic patient, or in bleeding thought to be driven by antiplatelet agents. The effect is fast but temporary (hours), so it's a bridge, not a cure — the definitive fix for uremic bleeding is dialysis and correcting the underlying problem.

Job 3: Von Willebrand disease and mild hemophilia A

In type 1 von Willebrand disease and mild hemophilia A, the patient has functional factor stored in the vessel walls — they just don't release enough at baseline. Desmopressin triggers release of that stored von Willebrand factor and factor VIII, raising levels enough to cover minor bleeding or procedures. It does not work in severe hemophilia (no stores to release) or in the types of von Willebrand disease where the factor is qualitatively abnormal — those need factor concentrate.

The trap that ties it together: hyponatremia

Here is the danger that catches people out. Desmopressin's whole job at the kidney is to retain free water. If a patient keeps drinking or receiving hypotonic fluids while desmopressin is on board, the retained water dilutes the sodium — and a fast drop in sodium can cause seizures and cerebral edema. This risk is highest in the hemostatic uses (where the goal has nothing to do with water), and in children and the elderly.

The other limit: tachyphylaxis

When desmopressin is used for its clotting-factor-releasing effect, repeated doses give less and less effect — the stores get depleted faster than they refill. This tachyphylaxis means you can't just keep redosing every few hours for ongoing bleeding; after a couple of doses the response fades and the team moves to factor concentrate or other measures. Knowing this keeps you from expecting a fourth dose to work like the first.

Bottom line

Desmopressin is the V2-selective ADH analog with three unrelated jobs: it replaces the missing hormone in central diabetes insipidus, it transiently fixes uremic and antiplatelet bleeding, and it releases stored factor in von Willebrand disease and mild hemophilia A. Track urine output and sodium in DI, respect the fast-but-temporary hemostatic effect, and never lose sight of the free-water hyponatremia trap or the tachyphylaxis that limits repeat dosing. Understand the one-receptor logic behind the three jobs and the drug stops being confusing — at the bedside and in the OR.

This article is general educational information for licensed clinicians and students, not medical advice or a substitute for your institution's protocols, pharmacy guidance, or a provider's orders. Always follow facility policy and verify doses independently.